CNW/ - GSK announced today that Health Canada has approved Ojjaara (momelotinib) for the treatment of splenomegaly and/or ...

Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, USA ...

Research results featured heavily in the news last week, first with Viking Therapeutics releasing promising early-stage data ...

The field of atopic dermatitis (AD) has been receiving great interest over the last few years with the approvals of both oral ...

New study reports protective effect among people with type 2 diabetes Kidney stones and the systemic conditions associated with them have a major impact on health and the economy in the US and ...

The global proton pump inhibitors (PPIs) market is currently valued at approximately USD 2.8 billion and is projected to grow ...

By Ayako Wakatsuki Pedersen, Ph.D., Senior Vice President of Translational Research at IO Biotech | Making the tumor microenvironment hostile to cancer cells and immune-suppressive cells may transform ...

s potential in the market. A key element is the company’s promising drug, denifanstat, a fatty acid synthase inhibitor, which has shown strong efficacy in Phase 2b trials, particularly among more ...

The study is evaluating AJ1-11095, a novel agent for the treatment of myelofibrosis that did not respond to or relapsed ...

Developed by Ascentage Pharma, lisaftoclax is a novel orally available Bcl-2 inhibitor with clinical benefits for an array of hematologic malignancies and solid tumors. At this year's ASH Annual ...

Patients with sarcoidosis treated with ACE inhibitors had greater mortality risk than those treated with angiotensin receptor blockers.

STORM Therapeutics Ltd. (STORM), the clinical stage company pioneering cellular reprogramming through RNA modifications to treat disease, ...